Effect of Alendronate in Patents with Osteoporosis and Chronic Kidney Disease
Phase 3
- Conditions
- Chronic Kidney Disease Stage 3a-3b.Chronic kidney disease, stage 3 (moderate)
- Registration Number
- IRCT20180506039549N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
Osteoporotic Patients with Chronic Kidney Disease
Patients over 18 years of Age
Exclusion Criteria
Patients with hyperparathyroidism
Patients with hypoparathyroidism
Patients with normal Densitometry
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone density in patients with Chronic Kidney Disease Stage 3a-3b. Timepoint: Before and 6 months after study. Method of measurement: Densitometry.
- Secondary Outcome Measures
Name Time Method